Showing 3881-3890 of 21442 results for "".
- SVF Enrichment Improves Fat Graft Retention in Randomized Breast Surgery Studyhttps://reachmd.com/news/svf-enrichment-improves-fat-graft-retention-in-randomized-breast-surgery-study/2488433/Stromal vascular fraction (SVF)-enriched autologous fat grafting (AFG) resulted in greater long-term graft retention than standard AFG in patients undergoing aesthetic and reconstructive breast procedures, according to results of a prospective, multicent
- Liposomal Bupivacaine Improves 72-Hour TKA Painhttps://reachmd.com/news/liposomal-bupivacaine-72-hour-tka-pain/2488424/Key Takeaways Older adults undergoing unilateral total knee arthroplasty under spinal anesthesia who received a postoperative four-in-one nerve block had lower pain scores with liposomal bupivacaine than with ropivacaine mainly from 24 to 72 hours, while early differences wer
- Norwegian OAT Study Tracks Switching, LAIB Uptake, Illicit Usehttps://reachmd.com/news/norwegian-oat-study-tracks-switching-laib-uptake-illicit-use/2488395/Key Takeaways In this Norwegian outpatient OAT cohort followed for nearly 3 years, most patients receiving LAIB, sublingual buprenorphine, or methadone remained on their original medication. Medication switching affected 13.2% of patients; 15 of those switches were t
- ALT/HDL May Improve Pediatric MASLD Screeninghttps://reachmd.com/news/althdl-may-improve-pediatric-masld-screening/2488400/Key Takeaways In a U.S. adolescent cohort paired with a Korean real-world pediatric cohort, ALT, ALT/AST, and ALT/HDL were associated with MASLD after adjustment. The derived ratios were similar to or slightly better than ALT alone, with ALT/HDL often performing best
- EEG-Guided Dexmedetomidine-Ketamine Improves Lumbar Fusion Recoveryhttps://reachmd.com/news/eeg-guided-dexmedetomidine-ketamine-improves-lumbar-fusion-recovery/2488381/Key Takeaways Older adults undergoing elective lumbar spine fusion had a smaller 24-hour decline in QoR-15 with a dexmedetomidine-ketamine multimodal protocol plus EEG-guided titration than with conventional balanced anesthesia. The multimodal approach was associated
- Cross-Sectional Coaxial Renal Biopsy Improved Adequacyhttps://reachmd.com/news/cross-sectional-coaxial-renal-biopsy-improved-adequacy/2488382/Key Takeaways In this single-center comparison of adult native kidney biopsies, the cross-sectional coaxial approach was associated with the highest specimen adequacy of the 3 ultrasound-guided techniques studied. It also produced the greatest glomerular yield, with
- Hippocampal-Avoidance WBRT Planning Improved with 4A-HGhttps://reachmd.com/news/hippocampal-avoidance-wbrt-planning-improved-with-4a-hg/2488320/Key Takeaways Across HA-WBRT plans generated on Halcyon and Edge, the four-arc hybrid geometry was associated with a better overall balance between whole-brain target coverage and hippocampal sparing than the open-field arc designs. More extensive convergence setting
- Review Integrates Functional and Aesthetic BTX-A Treatment for Facial Paralysishttps://reachmd.com/news/review-integrates-functional-and-aesthetic-btx-a-treatment-for-facial-paralysis/2488325/Botulinum toxin A (BTX-A) may offer dermatologists a way to address the functional, therapeutic, and aesthetic manifestations of facial paralysis within a single treatment framework, a recent review suggested.d BTX-A Targets Multiple Sequelae of Facial Paralysis The authors conduc
- Telehealth Care Improved Chronic Pain Sick Leave in Primary Carehttps://reachmd.com/news/telehealth-care-improved-chronic-pain-sick-leave-in-primary-care/2488312/Key Takeaways Among working-age adults on sick leave for chronic nonmalignant pain recruited from Swedish primary care, remote PCC added to usual care was associated with a significant 6-month advantage on the prespecified composite of self-efficacy and sick leave. D
- Mefatinib Improves PFS vs Gefitinib in EGFR-Mutated NSCLChttps://reachmd.com/news/mefatinib-pfs-gefitinib-egfr-mutated-nsclc/2488259/Key Takeaways In Chinese adults with untreated advanced EGFR-mutated nonsquamous non-small cell lung cancer receiving first-line mefatinib or gefitinib, progression-free survival was longer with mefatinib in the overall trial population. The clearest efficacy differe